Denis Lambrigts; David H. Sachs; David K. C. Cooper · 1998 · Transplantation
Paper
The pig-to-primate model is increasingly being utilized as the final preclinical means of assessing therapeutic strategies aimed at allowing discordant xenotransplantation. We review here the world experience of both pig-to-human and pig-to-nonhuman primate organ transplantation. Eight whole organ transplants using discordant mammalian donors have been carried out in human recipients; only one patient was reported (in 1923) to have survived for longer than 72 hr. Therapeutic approaches in the experimental laboratory setting have included pharmacologic immunosuppression, antibody and/or complement depletion or inhibition, the use of pig organs transgenic for human complement regulatory proteins, and conditioning regimens aimed at inducing a state of tolerance or specific immunologic hyporesponsiveness. The greatest success to date has been obtained with methods that inhibit complement-mediated injury, either by the administration of cobra venom factor or soluble complement receptor I to the recipient (with organ survival up to 6 weeks) or by the use of donor organs transgenic for human decay-accelerating factor (with organ survival up to 2 months). The future of xenotransplantation may lie in the judicious combination of current approaches.
Analysis
This review examines the pig-to-primate model for assessing xenotransplantation strategies, highlighting past human trials and experimental approaches to overcome rejection.
Discovery
Liu WB; Rui HL; Liu BL
Denner J
He Y; Peng Y; Liu Y; Jia J; Li L; Hara H; Feng S; Pan Z
Mulbjerg H; Ringgaard S; Agger P
Rao JS; Rangarajan P; Shetty A; Steinhoff M; Tran A; Crane AT; Low WC; Steer CJ; Ramachandran S
Bartley P. Griffith; Corbin E. Goerlich; Avneesh K. Singh; Martine Rothblatt; Christine L. Lau; Aakash Shah; Marc I. Lorber; Alison Grazioli; Kapil Saharia; Susie N. Hong; Susan Joseph; David Ayares; Muhammad M. Mohiuddin
Source record